An Open-Label, 2-Part, Single Dose, Randomized Study to Evaluate the Pharmacokinetics of combination etoricoxib/tizanidine tablets in Healthy Adult Subjects

• Conditions: Acute Pain in Musculoskeletal disorders; Musculoskeletal - Other muscular and skeletal disorders

• Registration Number: ACTRN12612001152819
• Lead Sponsor: Merck Sharp and Dohme Corp, a subsidiary of Merck & Co., Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-10-31
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 56

Inclusion Criteria

BMI < 30kg/m2
-Female of reproductive potential to have negative pregnancy test and agree to use double-barrier contraception
-Good health based on medical history, physical examination, vital sign measurements, ECG and laboratory assessments
-Non smoker

Exclusion Criteria

-History of emotional problems or clinically significant psychiatric disorder within 5yrs
-Clinically significant disease/disorder of any body systems
-Creatinine clearance of <80mL/min
-History of neoplastic disease
-Breast feeding mother
-History of stroke, chronic seizures or major neurological disorder
-Current use of prescription/non-prescription medication (includes oral contraception)-Consumes excessive amounts of alcohol
-Consumes excessive amounts of caffeine
-History of significant or severe allergies or anaphylactic reaction
-History of serious adverse experiences related to non-steroidal anti-inflammatory drug
-Regular user of illicit drugs

Study & Design

• Study Type: Interventional
• Study Design: Not specified